<DOC>
	<DOC>NCT02327182</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of 2 fixed dose of MT-4666 administered once daily for 52 weeks with or without receiving a concomitant acetylcholinesterase inhibitors (AChEIs), in patients with mild to moderate Alzheimer's Disease (AD).</brief_summary>
	<brief_title>Safety Study of MT-4666 in Subjects With Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Probable Alzheimer's disease consistent with the National Institute on Aging and the Alzheimer's Association Criteria for Diagnosis of Alzheimer's Disease (McKhann et al. 2011). MMSE score of ≥ 14 and ≤ 24 at the screening and ≥ 12 and ≤ 26 at the baseline. Modified Hachinski Ischemic Score (mHIS) ≤ 4 at the screening Appropriate caregiver available Subject living at home or in facilities who do not require continuous (24hour) nursing care. Diagnosis of any other disease which may cause dementia Diagnosis of major depressive disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) within last five years History of or current diagnosis of any psychosis History of myocardial infarction or unstable angina within six months before screening History of cerebrovascular disorder within 18 months before screening complication of hepatic disorder or renal dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>MT-4666</keyword>
	<keyword>α7 nicotinic acetylcholine receptor agonist</keyword>
	<keyword>Alzheimer's Disease</keyword>
	<keyword>Cognitive function</keyword>
	<keyword>Dementia</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>